Tags Archives: VV ECMO

Perfusfind S.L.

Abstract Continuous negative abdominal pressure (CNAP) therapy effectively provides respiratory support in patients with respiratory failure and severe obesity; however, its use in clinical practice remains limited. In this case,..

Perfusfind S.L.

Abstract Objectives: To describe clinical characteristics, mechanical ventilation strategies, and outcomes in patients with severe acute respiratory distress syndrome (ARDS) during weaning from venovenous extracorporeal membrane oxygenation (VV ECMO). Design: Retrospective, multicenter cohort..

Perfusfind S.L.

Abstract A 53 year old female was referred to our quaternary center for venovenous extracorporeal membrane oxygenation (ECMO) retrieval. Following a brief admission for a cosmetic procedure, she had represented..

Perfusfind S.L.

Abstract Background Use of venovenous extracorporeal membrane oxygenation (ECMO) is increasing, but candidacy selection processes are variable and subject to bias. Research Question What are the reasons behind venovenous ECMO..

Perfusfind S.L.

Abstract Microfluidic membrane oxygenators are designed to mimic branching vasculature of the native lung during extracorporeal lung support. To date, scaling of such devices to achieve clinically relevant blood flow..

Perfusfind S.L.

Abstract Purpose: Venovenous extracorporeal membrane oxygenation (VV-ECMO) can be used to support patients with refractory acute respiratory failure, though guidance on patient selection is lacking. While age is commonly utilized..

Perfusfind S.L.

Abstract Background Central nervous system (CNS) injury following initiation of veno-venous extracorporeal membrane oxygenation (VV-ECMO) is common. An acute decrease in partial pressure of arterial carbon dioxide (PaCO2) following VV-ECMO..

Perfusfind S.L.

Abstract Refractory hypoxemia (RH) during venovenous extracorporeal membrane oxygenation (VV ECMO) support is a complex problem that limits the benefit of this therapy. The need for sustained deep sedation and..

Perfusfind S.L.

Abstract Objective To identify and compare the rates of cannula-associated  (CaDVT)  on venovenous  (VV-ECMO) who receive systemic  (AC) and those who do not receive AC. Design Retrospective observational study. Setting Tertiary academic medical center...

Perfusfind S.L.

Abstract Importance: Skin pigmentation influences peripheral oxygen saturation (SpO2) measured by pulse oximetry compared to the arterial saturation of oxygen (SaO2) measured via arterial blood gas analysis. However, data on..

Perfusfind S.L.

Abstract Objectives We aimed to evaluate thrombotic and hemorrhagic complications with heparin versus bivalirudin use in veno-venous extracorporeal membrane oxygenation (V-V ECMO). Methods We performed a retrospective cohort study of..

Perfusfind S.L.

Abstract Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a life-saving therapy for critically ill patients, but it carries an increased risk of thrombosis due to blood interacting with non-physiological surfaces. While..

Perfusfind S.L.

Abstract Unfractionated heparin (UFH) is the most used anticoagulant in patients receiving veno-venous extracorporeal membrane oxygenation (VV-ECMO). Its therapeutic levels are monitored using activated partial thromboplastin time ratio (aPTTr) or..

Perfusfind S.L.

Abstract Importance  Prone positioning may improve outcomes in patients with severe acute respiratory distress syndrome (ARDS), but it is unknown whether prone positioning improves clinical outcomes among patients with ARDS who..

Perfusfind S.L.

Abstract Rationale: Definitive guidelines for anticoagulation management during veno-venous extracorporeal membrane oxygenation (VV ECMO) are lacking, while bleeding complications continue to pose major challenges. Objectives: To describe anticoagulation modalities and..

Perfusfind S.L.

Abstract A restrictive fluid strategy is recommended in patients with acute respiratory distress syndrome (ARDS) managed with venovenous extracorporeal membrane oxygenation (VV ECMO). However, there are no established predictors for..

Perfusfind S.L.

Abstract Mortality prediction for patients with the severe acute respiratory distress syndrome (ARDS) supported with veno-venous extracorporeal membrane oxygenation (VV-ECMO) is challenging. Clinical variables at baseline and on day 3..

Perfusfind S.L.

Abstract Background: Extubation while receiving V-V ECMO is being considered earlier for patients with respiratory failure. This can facilitate early mobilization, participation in physical therapy, and reduce the potential consequences of..

Perfusfind S.L.

Abstract Introduction Most patients on extracorporeal membrane oxygenation (ECMO) decease during therapy on the system. However, the actual causes of death have not been studied sufficiently. This study analyses the..

Perfusfind S.L.

Abstract Background: Hospitalized COVID-19 patients with hypoxemic respiratory failure may deteriorate despite invasive mechanical ventilation and thus require extracorporeal membrane oxygenation (ECMO) support. Unfractionated heparin (UFH) is the antithrombotic of..

Perfusfind S.L.

Abstract Obesity is associated with an overall increased risk of morbidity and mortality. However, in patients with critical illness, sepsis, and acute respiratory distress syndrome, obesity may be protective, termed..

Perfusfind S.L.

Abstract Introduction and Methods We examined the relationship between 24-h pre- and post-cannulation arterial oxygen tension (PaO2) and arterial carbon dioxide tension (PaCO2) and subsequent acute brain injury (ABI) in..

Perfusfind S.L.

Abstract Purpose Ultraprotective ventilation in  (ARDS) patients with veno-venous  (VV ECMO) reduces mechanical power (MP) through changes in positive end-expiratory pressure (PEEP); however, the optimal approach to titrate PEEP is unknown. This..

Perfusfind S.L.

This case reports on a 41-years old male with no significant medical history who was admitted to the emergency room following 25% total body surface area (TBSA) deep partial thickness..

Perfusfind S.L.

Abstract Objective:  Analysis of the prevalence and risk factors for weaning failure from venovenous extracorporeal membrane oxygenation (VV-ECMO) in patients with severe acute respiratory insufficiency. Design:  Single-center retrospective observational study. Setting:  Sixteen beds medical ICU at the University..

Perfusfind S.L.

Abstract Background Extracorporeal membrane oxygenation (ECMO) is a recognized method of support in patients with severe and refractory acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 infection. While veno-venous (VV)..

Perfusfind S.L.

Abstract Patients with respiratory failure may remain hypoxemic despite treatment with venovenous extracorporeal membrane oxygenation (VV-ECMO). Therapeutic hypothermia is a potential treatment for such hypoxia as it reduces cardiac output (�˙�) and oxygen consumption. We modified a previously..

Perfusfind S.L.

Abstract Mechanical ventilation for respiratory failure due to COVID-19 is associated with significant morbidity and mortality. Veno-venous extracorporeal membrane oxygenation (ECMO) is an attractive management option. This study sought to determine the effect..

Perfusfind S.L.

Abstract Severe acute refractory respiratory failure is considered a life-threatening situation, with a high mortality of 40 to 60%. When conservative oxygenation methods fail, a lifesaving measure is the introduction..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is used in critically ill patients with severe pulmonary and/or cardiac failure. Blood is drained from the venous system and pumped through a membrane oxygenator..